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OBJECTIVES The purpose of this study was to assess whether the immediate availability of serum markers
would increase the appropriate use of thrombolytic therapy.
BACKGROUND Serum markers such as myoglobin and creatine kinase, MB fraction (CK-MB) are effective
in detecting acute myocardial infarction (AMI) in the emergency setting. Appropriate
candidates for thrombolytic therapy are not always identified in the emergency department
(ED), as 20% to 30% of eligible patients go untreated, representing 10% to 15% of all patients
with AMI. Patients presenting with chest pain consistent with acute coronary syndrome were
evaluated in the EDs of 12 hospitals throughout North America.
METHODS In this randomized, controlled clinical trial, physicians received either the immediate
myoglobin/CK-MB results at 0 and 1 h after enrollment (stat) or conventional reporting of
myoglobin/CK-MB 3 h or more after hospital admission (control). The primary end point
was the comparison of the proportion of patients within the stat group versus control group
who received appropriate thrombolytic therapy. Secondary end points included the emergent
use of any reperfusion treatment in both groups, initial hospital disposition of patients
(coronary care unit, monitor or nonmonitor beds) and the proportion of patients appropriately
discharged from the ED.
RESULTS Of 6,352 patients enrolled, 814 (12.8%) were diagnosed as having AMI. For patients having
AMI, there were no statistically significant differences in the proportion of patients treated
with thrombolytic therapy between the stat and control groups (15.1% vs. 17.1%, p 5 0.45).
When only patients with ST segment elevation on their initial electrocardiogram were
compared, there were still no significant differences between the groups. Also, there was no
difference in the hospital placement of patients in critical care and non–critical care beds. The
availability of early markers was associated with more hospital admissions as compared to the
control group, as the number of patients discharged from the ED was decreased in the stat
versus control groups (28.4% vs. 31.5%, p 5 0.023).
CONCLUSIONS The availability of 0- and 1-h myoglobin and CK-MB results after ED evaluation had no
effect on the use of thrombolytic therapy for patients presenting with AMI, and it slightly
increased the number of patients admitted to the hospital who had no evidence of acute
myocardial necrosis. (J Am Coll Cardiol 2000;36:1500–6) © 2000 by the American College
of Cardiology
It has been unequivocally demonstrated that thrombolytic
therapy improves survival in patients with ST segment
elevation acute myocardial infarction (AMI) (1–3). The
proportion of patients treated, however, is less than what
would be projected from both clinical trial and registry data
(4–7). For example, electrocardiographic (ECG) findings
from 6,000 consecutive patients with AMI admitted to the
hospital who were included in the Myocardial Infarction,
Triage and Intervention Project indicated that ST segment
elevation or new bundle branch block was evident in .50%
of patients on the initial ECG (4–6). Yet, thrombolytic
therapy was prescribed to only 25% to 30% of these patients
(6,7). Retrospective assessment of patient eligibility for
therapy consistently suggested that up to 10% to 25% more
of these patients were appropriate candidates for treatments
(6,7). The reasons for this discrepancy are unclear.
Arrival to the hospital after 12 h, contraindications to
thrombolytic therapy, older age and atypical or resolving
symptoms account for many, but not all, decisions to
withhold treatment. Failure to initially recognize ST seg-
ment elevations on the 12-lead ECG or misunderstanding
of the significance of lesser levels of chest pain can also lead
to underutilization of therapy. In one study, 20% of appar-
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ently eligible patients who were ,75 years of age and
presented to the hospital within 6 h did not receive
thrombolytic therapy (8). In another study, 16% of all
patients with ST segment elevation infarcts were not ini-
tially recognized (9).
Serial testing for the early serum markers of myocardial
necrosis, myoglobin and creatine kinase, MB fraction (CK-
MB) is an effective method for identifying patients with
AMI (10–13). Myoglobin levels are elevated in over two-
thirds of patients with AMI at the time of presentation to
the emergency department (ED) and are present in the
serum of virtually all within 6 h after symptom onset (10).
Elevated levels of CK-MB are present in ;40% of patients
on initial hospital presentation. This proportion increases to
.90% of patients with AMI having positive CK-MB levels
by 6 h after ED presentation (11,13). The routine use of
sensitive serum markers of myocardial necrosis in the very
early period after presentation to the ED may provide an
incremental aid for identifying patients with evolving AMI,
particularly in those with less obvious symptoms and less
profound ECG abnormalities.
In the Serial Markers, Acute Myocardial Infarction and
Rapid Treatment Trial (SMARTT), we assessed the impact
of using immediate (0 and 1 h) serial myoglobin and
CK-MB determinations (stat) on the use of thrombolytic
therapy in patients with AMI in the emergency setting. Our
hypothesis was that the availability of serial early cardiac
serum markers would lead to a 25% relative increase in the
proportion of patients receiving appropriate thrombolytic
therapy in the ED. We also sought to determine whether
such testing would influence the rate of coronary care unit
(CCU) admission and direct discharge from the ED.
METHODS
Setting. The SMARTT study was a multicenter, prospec-
tive, randomized, controlled clinical trial conducted in 12
academic, community and military hospitals in the United
States and Canada with active emergency centers (see
Appendix). Patients were randomized using a central tele-
phone system, and data were collected and analyzed at a
central coordinating center in Seattle, Washington. The
ECG data were centrally read in a blinded fashion at the
Ischemia Monitoring Core Laboratory, Duke Clinical Re-
search Institute, Durham, North Carolina, and serum sam-
ples were sent to a core laboratory at the University of
Cincinnati for quality assurance testing and determination
of myoglobin and CK-MB in the control group.
Protocol design. The SMARTT study included a prospec-
tive, observational pilot phase analyzing the sensitivity and
specificity of the serum markers in a chest pain population
(14). In this pilot study, an optimal early serum marker
sensitivity rate of 70.8% was determined at 0 and 1 h after
hospital presentation for myoglobin or CK-MB. The pilot
trial was then followed by a prospective, randomized trial in
which half of the patients at each center had “stat” testing
results reported within the first 3 h, whereas in the “control”
group, blood was drawn but testing or reporting was delayed
until at least 3 h or more.
Patients were eligible for enrollment in the study if they
presented to the ED of the participating hospitals with
chest pain consistent with a possible acute coronary syn-
drome. All participants were able to give informed consent.
Exclusions for the study were age ,25 years, altered mental
status, pregnancy or inability or unwillingness to have a
follow-up evaluation. Patients whose chest pain was obvi-
ously noncardiac, on the basis of history, physical examina-
tion or X-ray findings, were also excluded, as were patients
with ST segment elevation treated with reperfusion at the
time of the initial evaluation. Thus, the target group
included those patients whose treating physician was uncer-
tain as to the cause of chest pain. All patients included in the
trial had ECGs performed as part of their initial ED
evaluation.
After informed consent was provided, blood was drawn,
which was transported to the site laboratory under special
identification. The laboratory technician then called a cen-
tral telephone randomization center that provided the allo-
cation assignment. Control samples were frozen and
shipped to the core laboratory for quality assurance of site
readings. Positive cardiac serum markers were defined as
levels .100 ng/ml for myoglobin and .6 ng/ml for
CK-MB. The ECG readings were also independently
verified. ST segment elevation was defined as .1 mV in two
contiguous limb leads or .2 mV in two contiguous anterior
leads. Routine baseline, 6- to 8-h and 12- to 18-h CK and
CK-MB results were obtained for all patients admitted to
the hospital. “Acute myocardial infarction” was defined by
World Health Organization criteria as elevation of CK-MB
in a characteristic pattern, as measured by serial blood
samples, or the evolution of ECG changes after presenta-
tion in patients with chest pain. Patients were treated
according to the standard of care at each institution. In the
stat marker assessment group, the results of the 0- and 1-h
CK-MB and myoglobin testing were made available to the
treating emergency physician immediately, allowing clinical
decisions to be made with the results at hand. In the control
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CCU 5 coronary care unit
CK-MB 5 creatine kinase, MB fraction
ECG 5 electrocardiogram
ED 5 emergency department
EMCREG 5 Emergency Medicine Cardiac Research
Group
LBBB 5 left bundle branch block
PTCA 5 percutaneous coronary transluminal
angioplasty
SMARTT 5 Serial Markers, Acute Myocardial Infarc-
tion and Rapid Treatment Trial
stat 5 immediate (0 and 1 h myoglobin/CK-MB)
1501JACC Vol. 36, No. 5, 2000 Gibler et al.
November 1, 2000:1500–6 SMARTT Trial
group, the results of any cardiac serum marker testing were
withheld by the laboratory for $3 h before being released.
Patients were followed during their stay in the ED and
subsequent hospital stay to determine the outcome. In
addition to the primary diagnosis, the date and time of
discharge to home or admission to the hospital were
ascertained, as well as the type of hospital ward (CCU,
unmonitored bed or monitored non-CCU bed) for admit-
ted patients. Admitted patients were followed to determine
their final diagnosis (International Classification of Dis-
eases, 9th Revision), with AMI confirmed by cardiac marker
elevation and ECG changes. Any in-patient cardiovascular
complications were also documented. The date and time of
thrombolytic therapy, coronary angiography, coronary an-
gioplasty or coronary artery bypass graft procedures were
also recorded. Patients discharged directly from the ED
were contacted at 7 to 14 days by telephone or letter. Any
subsequent readmissions, myocardial infarctions or deaths
were documented.
Outcome measures. The primary end point was the pro-
portion of patients treated with thrombolytic therapy within
3 h of ED presentation. Secondary end points included the
use of any emergent reperfusion treatment, including
thrombolytic therapy or primary percutaneous transluminal
coronary angioplasty (PTCA), within 3 h of hospital pre-
sentation, the percentage of patients who received treatment
and who did not meet ECG criteria (ST segment elevation
or new bundle branch block) on their initial ECG in the ED
and initial patient disposition from the ED, including the
proportion of patients discharged home or admitted to
non-CCU beds.
Sample size and statistical analysis. The sample size for
the randomized trial was calculated to detect a 25% relative
increase in thrombolytic therapy utilization in the subset of
patients with AMI determined by standard cardiac enzyme
testing at each medical center (.2 times elevation in CK or
CK-MB in any of the 0- to 16-h samples) or characteristic
ECG changes. The sample size necessary to detect this
difference (alpha 5 0.05, beta 5 0.2) was 815 patients with
AMI per group. We estimated from retrospective data that
enrollment of a total of 7,000 patients would generate 1,630
patients with AMI. A Data and Safety Monitoring Board
analyzed the data at predefined interim points.
The stat and control groups were compared using a
two-tailed chi-square test; p , 0.05 was considered signif-
icant. When there were significant differences between the
stat and control groups at baseline, analyses were performed
after adjustment using the Mantel-Haensel test. All statis-
tical analyses were carried out using the SAS statistical
package. The study was approved by each medical center’s
Human Subjects Review Committee.
RESULTS
Of the 6,388 patients enrolled in the randomized trial, 36
were excluded because of insufficient data (Fig. 1). Most of
these lacked in-hospital serum marker data sufficient to be
assigned to AMI versus non-AMI groups by protocol
definition. None received reperfusion treatment. Of the
patients who were discharged from the ED, follow-up was
obtained in 96.4%. The trial was discontinued before
enrolling the target sample size when it became apparent
that there were no trends toward significant differences in
the primary outcome between the stat and control groups.
Of the 6,352 patients with complete data evaluated in this
trial, 3,178 were randomized to the stat group and 3,174
were randomized to the control group. Of these, 1,901
patients (29.9%) were discharged home from the ED,
whereas 4,451 were admitted to the hospital. For the trial,
814 patients (12.7%) had enzyme evidence of AMI per
protocol: 410 in the stat group and 404 in the control group.
Patient demographic data. Baseline characteristics for pa-
tients enrolled in SMARTT are summarized in Table 1.
Patients with AMI proved to be older than those without
AMI (64 years old [25%, 75% 5 55 years old, 74 years old]
vs. 59 years old [25%, 75% 5 48 years old, 71 years old]
[p 5 0.0006]) and were more likely to be male (p 5 0.001),
have a history of myocardial infarction (p 5 0.003), have
diabetes (p 5 0.006) and have a history of hypercholester-
olemia (p 5 0.016). A greater number of patients with AMI
were current smokers (p 5 0.003).
The median time to ED presentation from symptom
onset in patients with and without AMI is shown in Table
1. There was a statistically significant difference in time to
arrival between the stat and control groups in patients with
AMI (p 5 0.0014), but not in patients without AMI (p 5
0.34). For patients with AMI, hospital arrival to treatment
with thrombolytic therapy was nearly identical: 2.9 h (25%,
75% 5 0.7 h, 1.9 h) for stat patients versus 2.5 h (25%, 75%
5 0.6 h, 1.4 h) for control subjects. The discharge diagnoses
for the two groups are listed in Figure 2. There were no
significant differences in the percentages of patients in each
group with AMI, unstable angina, stable angina or unspec-
ified chest pain. In the 814 patients subsequently diagnosed
with AMI, the initial ECG findings are shown in Figure 3.
There were no significant differences between the two
Figure 1. Patient flow and follow-up diagram. (Discharged 5 D/Ced)
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groups in the percentages of patients with ST segment
elevation, left bundle branch block (LBBB) or new Q waves.
Serum marker results. Serum enzyme results for the pa-
tients in the randomized trial are shown in Table 2. Of the
6,352 patients in the trial, 16.7% had positive myoglobin
results and 9.6% had positive CK-MB results at 0 or 1 h
after ED presentation. Of the patients randomized to the
stat group, 19.2% had positive CK-MB or myoglobin
studies in the ED, compared with 19.3% in the control
group (p 5 0.905). Of the 814 patients who were diagnosed
with myocardial infarction, 64.1% had positive myoglobin
studies in the ED at either 0 or 1 h after presentation
(sensitivity 64.1%, specificity 90.2%), 52.6% had positive
CK-MB studies at either 0 or 1 h (sensitivity 52.6%,
specificity 96.7%) and 72% had either positive CK-MB or
myoglobin at 0 or 1 h after presentation (sensitivity 72%,
specificity 88.5%). Of patients diagnosed with AMI, 69% in
the stat group had positive cardiac serum markers in the
ED, compared with 75% in the control group (p 5 0.06).
Reperfusion therapy. For the primary end point in
SMARTT, the proportion of all patients with AMI treated
with thrombolytic agents in the stat group within 3 h after
randomization was 15.1%, as compared with 17.1% in the
control group, which had serum marker results delayed for
$3 h (p 5 0.45). Of the patients in the stat group, 21.7%
received either thrombolytic therapy or primary PTCA
within 3 h of randomization, compared with 24.5% in the
control group (p 5 0.34).
When the subset of patients with ST segment elevation
and AMI were analyzed, there remained no differences
between the groups in the use of thrombolytic therapy alone
(39.5% for stat vs. 42.1% for control; p 5 0.70) or with
thrombolysis or PTCA (58.5% for stat vs. 64.2% for control;
p 5 0.42). Likewise, when patients with LBBB on the
presenting ECG were analyzed, there were no differences in
thrombolytic therapy or PTCA utilization between the
groups, either when AMI was subsequently diagnosed or
when it was not.
Of 2,868 patients diagnosed without AMI, six patients
(0.2%) in the stat group and 10 (0.36%) of 2,770 patients in
the control group received thrombolytic therapy or PTCA
within 3 h of randomization (p 5 NS). No adverse
outcomes were observed. Looking more closely at the effects
of positive cardiac markers in the ED, we analyzed the rate
of thrombolytic therapy utilization in patients with positive
serum markers and either ST segment elevation or nonspe-
cific ECG findings on their initial ECG in the ED. In
Figure 2. Discharge diagnoses: All trial patients, comparing stat versus
control groups. P 5 NS for all comparisons.
Figure 3. Electrocardiographic findings in all patients with AMI, compar-
ing stat versus control groups.
Table 1. Baseline Characteristics: Randomized Trial
Non-AMI AMI
p Value†
Stat*
(n 5 2,768)
Control
(n 5 2,770)
Stat
(n 5 410)
Control
(n 5 404)
Mean age (yrs) 59.9 59.1 63.4 64 0.0006
Gender (% male) 56 56 66 70 0.001
Medical histories (%)
Hypertension 54 54 54 56 NS
Previous MI 32 30 37 36 0.003
Congestive heart failure 14 15 16 15 NS
Coronary artery bypass graft surgery 15 16 14 14 NS
Percutaneous transluminal coronary angioplasty 19 18 13 18 NS
Diabetes 21 22 27 25 0.006
Hypercholesterolemia 26 26 31 29 0.016
Current smoking 27 27 34 30 0.003
Time from symptom onset to ED arrival in
median hours (25%, 75% percentiles)
3 (1.4, 6.0) 2.8 (1.3, 6.2) 2.2‡ (1.1, 5.9) 2.7 (1.2, 7.2) NS
*There were no significant differences between the stat and control groups for all variables in the non-AMI and AMI groups. †Non-AMI vs. AMI. ‡In patients with AMI, the
difference in time from symptom onset to arrival at the hospital in stat vs. control groups (p 5 0.0014).
AMI 5 acute myocardial infarction; ED 5 emergency department; MI 5 myocardial infarction; NS 5 not significant; stat 5 immediate (0 and 1 h) serial myoglobin and
creatine kinase, MB fraction determinations.
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patients with ST segment elevation and positive cardiac
serum markers in the ED, 44.2% in the stat group received
thrombolytic therapy within 3 h, compared with 44.6% in
the control group (p 5 0.993). In patients without ST
segment elevation, but with positive cardiac serum markers
in the ED, no patient in either group was treated with
thrombolytic therapy or primary PTCA within 3 h. To
determine whether positive cardiac serum markers in the
ED resulted in inappropriate treatment of patients without
AMI, we analyzed thrombolytic therapy use in patients with
positive cardiac serum markers in the ED who were subse-
quently not diagnosed with AMI (false positive cardiac
serum markers in the ED). In these patients, 0.76% in the
stat group were treated with thrombolytics within 3 h,
compared with 0.43% in the control group (p 5 0.641).
Hospital disposition. Discharge rates and hospital utiliza-
tion are indicated for the two groups in Figure 4. There
were no significant differences between the groups in the
distribution of admissions to the CCU, monitored or
nonmonitored beds. A total of 1,901 patients (29.8%) were
discharged home from the ED. In the stat group, 901
(28.4%) of 3,178 patients and 1,000 (31.5%) of 3,174
patients in the control group were released. This difference
was statistically significant (p 5 0.023). There was no
difference in the length of hospital stay between the stat and
control groups for patients with or without AMI.
DISCUSSION
Early detection of AMI. Over the past decade, multiple
studies have examined the sensitivity and specificity of
several early serum markers for detecting myocardial necro-
sis in the emergency setting. New technology has made it
possible to have stat testing and reporting of these serum
markers in ,1 h after a blood sample is obtained, allowing
for “real-time” decision-making in the ED. To date, no
study has been done to determine whether this information
affects initial clinical decision-making regarding reperfusion
therapy. Myoglobin (molecular weight [mw] 17,000 dal-
tons) and CK-MB (mw 82,000 daltons), in particular, have
emerged as effective early markers of myocardial necrosis
(10–15). One large study suggests that early elevation of
these markers indicates greater risk of ischemic complica-
tions for the patient (16).
Treatment decisions. Serum markers of myocardial necro-
sis, typically analyzed retrospectively in most studies, have
not been extensively evaluated for a real-time impact on
physician decision-making in the ED. Two studies con-
ducted by the Emergency Medicine Cardiac Research
Group (EMCREG) demonstrated that emergency physi-
cians would use stat serum CK-MB levels in their evalua-
tion of patients with a nondiagnostic ECG and a possible
acute coronary syndrome presenting to the ED (17,18). The
EMCREG-3 study evaluated the potential utility of 0- and
3-h serum markers in 1,042 patients presenting to the ED
with nondiagnostic ECGs. Using 0- and 3-h sampling,
elevated CK-MB levels resulted in statistically significant
increases in the disposition of patients from the ED to a
CCU, whereas negative CK-MB levels tended to influence
emergency physicians to admit these patients to a less intensive
care setting of the hospital. An important finding was that a
negative CK-MB level did not result in the inappropriate
discharge of patients with unstable angina to home (18).
This study was designed to clarify the impact of having
CK-MB and myoglobin results available on the initial
clinical decision-making. It is important to emphasize that
all EDs participating in this trial were staffed by Board-
eligible/Board-certified emergency physicians with exten-
sive experience in evaluating patients with chest pain and
treating AMI. In the U.S., elevated cardiac serum markers
are not typically used, without typical ST segment elevation,
to identify candidates for treatment with thrombolytic
therapy. By providing rapid availability of myoglobin and
CK-MB to the emergency physician, we anticipated that
elevated levels would potentially increase awareness of an
evolving AMI and stimulate appropriate administration of a
fibrinolytic agent to these patients.
In this trial, myoglobin and CK-MB levels drawn at 0
and 1 h and made available to the clinician did not increase
the proportion of patients with AMI, with or without ST
segment elevation, receiving thrombolytic therapy or pri-
mary PTCA. Patients with LBBB, a nonspecific indicator
of patients who will benefit from thrombolytic therapy, also
did not have increased administration of thrombolytic
therapy in the ED. Even when only patients with positive
cardiac markers in the ED were analyzed, there was no
increase in reperfusion therapy noted in patients whose
serum marker results were available to the treating ED
clinician. Importantly, the availability of “stat” serum mark-
Figure 4. Hospital disposition: all trial patients, comparing stat versus
control groups.
Table 2. Sensitivity and Specificity of Serum Markers for Acute
Myocardial Infarction*
Marker Sensitivity (%) Specificity (%)
Myoglobin 64.1 90.2
CK-MB 52.6 96.7
Either myoglobin or CK-MB 72 88.5
*Sensitivity and specificity of markers at either 0 or 1 h after arrival at the emergency
department.
CK-MB 5 creatine kinase, MB fraction.
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ers did not increase the inappropriate use of thrombolytic
therapy in patients without ST segment elevation or in
patients who were subsequently not diagnosed with AMI.
Disposition decisions. The results of two previous studies
of resource utilization were not confirmed in this trial
(17,18). No difference in CCU admissions was observed for
either group. A statistically significant difference was seen,
however, in the discharge of patients to home from the ED
(28.4% in the stat group vs. 31.5% in the control group).
Contact with patients discharged from the ED within the
first two weeks, or subsequent review of their medical
records over longer periods, did not reveal excessive isch-
emic complications in the stat versus control group.
Study limitations. The lack of impact of 0- and 1-h myo-
globin and CK-MB levels on physician decision-making in the
emergency setting in SMARTT may be due to several factors.
Elevation of a sensitive but nonspecific indicator of myocardial
necrosis, such as serum myoglobin, may not be a sufficient
stimulus for the physician to increase surveillance for ST
segment elevation on the initial 12-lead ECG. A positive
myoglobin in the first hour, combined with a negative CK-MB
level in this period, may actually have had a negative influence
on physician behavior. Negative serum levels of CK-MB, a
relatively specific indicator of myocardial necrosis, may have
influenced the decision not to start treatment, as the elevation
of myoglobin may have been considered falsely positive. Zero-
and 1-h determinations of myoglobin and CK-MB were
chosen from the pilot trial to maximize the earliest possible
time to treatment with thrombolytic therapy, rather than to
maximize diagnostic capability. Studies suggest the optimal
diagnostic window for myoglobin and CK-MB is 0 and 3 h, so
the full impact of these serum markers on physician decision-
making, especially resource allocation, may not have been
realized by our trial (10–13,19–24). In addition, patients with
AMI in the stat group presented earlier (2.2 h) than those in
the control group (2.7 h). It would be expected, owing to
release kinetics of the serum markers myoglobin and CK-MB,
that patients with AMI in the stat group would therefore be
less likely to have early cardiac serum marker elevation influ-
encing the decision of the clinician to administer thrombolytic
therapy. This is also supported by the finding that 69% of the
stat group had positive cardiac serum markers in the ED,
compared with 75% in the control group, whose members
arrived at the ED later.
The magnitude of the impact of a negative or positive
CK-MB level on resource utilization (CCU, monitored,
nonmonitored beds) may not be realized owing to our study
design. By contrast, the role of serum markers in helping to
identify patients who can be safely discharged from the ED
appears to be substantiated by this study. Clinicians under-
standing the release kinetics of these serum markers, and
thus expecting negative cardiac serum marker results in this
very early period, may have felt more comfortable discharg-
ing patients after a negative clinical evaluation and negative
cardiac serum markers over a 3-h period and a nondiagnos-
tic 12-lead ECG, rather than basing their decision to discharge
the patient from the ED on “stat” serum marker data available
in 1 h. Further study is necessary to evaluate the impact of early
cardiac serum markers on clinical decision-making in the
emergency setting, perhaps with blood samples timed to
maximize diagnostic accuracy or trials exploring more specific
cardiac markers such as troponin T or I (25–29).
APPENDIX
Investigators and Study Sites for SMARTT
Co-Principal Investigators: W. Douglas Weaver, MD,
and W. Brian Gibler, MD
Writing Subcommittee: W. Brian Gibler, MD, James W.
Hoekstra, MD, and W. Douglas Weaver, MD
Data Coordinating Center: MITI, University of Washing-
ton Medical Center, Seattle, Washington: W. Douglas Weaver
(Principal Investigator), Alfred Hallstrom, PhD (Chief
Biostatistician), Nathan R. Every, MD, Jenny Martin, RN
(Study Coordinator), Mark Wirkus, MS (Statistical Ana-
lyst), Brad Bisson, MS, Paul Frederick MPH, MBA
Core Biochemical Laboratory: University of Cincinnati
Medical Center, Cincinnati, Ohio: W. Brian Gibler, MD
(Principal Investigator), I-Wen Chen, PhD, Matthew
Sperling, BA
Core ECG Laboratory: Duke University Medical Center,
Durham, North Carolina: Mitchell Krucoff, MD (Principal
Investigator)
Participating Centers: William Beaumont Hospital, Royal
Oaks, Michigan: Raymond Jackson, MD (Principal Investi-
gator) (n 5 1,205); University of Cincinnati, Cincinnati,
Ohio: Michael R. Sayre, MD (Principal Investigator), Vic-
toria Castelli, RN (n 5 1,147); St. Paul Hospital, Vancouver,
British Columbia: James Christenson, MD (Principal Inves-
tigator) (n 5 784); Ohio State University, Columbus, Ohio:
James W. Hoekstra, MD (Principal Investigator) (n 5 775);
Maine Medical Center, Portland, Massachusetts: George Hig-
gins, MD (Principal Investigator), Costas Lambrew, MD
(n 5 615); University of Alabama, Birmingham, Alabama:
Janet Pribble, MD (Principal Investigator) (n 5 560); Royal
Columbian Hospital, New Westminster, British Columbia:
Grant Innes, MD (Principal Investigator) (n 5 493);
University of Washington Medical Center, Seattle, Washing-
ton: Mickey Eisenberg, MD (Principal Investigator) (n 5
288); Portland Veterans Affairs Hospital, Portland, Oregon:
Richard Harper, MD (Principal Investigator), James Bryan,
MD (n 5 260); Highland Hospital, Oakland, California:
Gary Young, MD (Principal Investigator), M. Andrew
Levitt, DO (n 5 119); Harborview Hospital, Seattle, Wash-
ington: W. Douglas Weaver, MD (Principal Investigator)
(n 5 108); Madigan Army Medical Center, Tacoma, Wash-
ington: Steve Pace, MD (Principal Investigator) (n 5 34).
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